| Literature DB >> 29727668 |
Christopher G Parker1, Benjamin F Cravatt2.
Abstract
Matching genetically defined cancer states to drugs that specifically target these states is a principal goal of personalized oncology medicine. In this issue, McMillan et al. show how large-scale chemical screening coupled to deep molecular profiling can identify mechanistically diverse druggable vulnerabilities for genetic subtypes of lung cancers.Entities:
Mesh:
Year: 2018 PMID: 29727668 DOI: 10.1016/j.cell.2018.04.020
Source DB: PubMed Journal: Cell ISSN: 0092-8674 Impact factor: 41.582